Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
50 participants
INTERVENTIONAL
2013-06-30
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Congestive Heart Failure Pilot Study Utilizing Wireless Home Scale and Daily Symptom Monitoring
NCT03234088
Serial Measurements of Biomarker in Patients With Acute Decompensated Heart Failure
NCT00514384
Assessment of Heart Failure (HF) At-Home Management Solution ADI Cardio Pulmonary Monitoring System (CPM)
NCT05980585
Acute Heart Failure With Preserved Ejection Fraction - COngestion Discharge Evaluation
NCT04343430
Electronic S3 Prediction of Hospital Readmissions for HF Exacerbation
NCT04112849
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
We will investigate whether respiratory parameters during re-compensation are related to the therapy effects and changes in pulmonary congestion status. This study will collect data in an observational and clinical setting in the re-compensation phase of ADHF.
Correlation between measured lung and respiratory parameters and standard clinical parameters characterizing stages of re-compensation will be undertaken. Standard clinical parameters may include diuretics and other cardiac medication dose frequency, weight, heart rate, respiratory rate, chest x-rays (when routinely performed), symptoms such as shortness of breath or fatigue, biomarkers such as brain natriuretic peptide (BNP), stroke volume, cardiac output, and oxygen requirements.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Respiratory Parameters Measurements
non-invasive respiratory parameter measurements
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
non-invasive respiratory parameter measurements
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Able and willing to provide written informed consent or not able to give informed consent because of mechanical respiration
3. Diagnosis of acute or chronic decompensated heart failure with pulmonary congestion or edema
4. Systolic blood pressure \>80 mm Hg at time of enrollment
5. Resting pulse oximetry (SpO2) at the time of enrollment of at least 88% at 21% iron oxides (FeO2)
6. Agreement to be measured with the study devices according to study protocol by patient or legal representative
7. Left ventricular ejection fraction (LVEF) \< 40% in 3D- Echocardiography
Exclusion Criteria
2. Surgery of the upper airway, nose, sinus or middle ear within the last 90 days
3. Major medical or psychiatric condition that would interfere with the demands of the study or the ability to complete the study. For example, severe unstable chronic lung disease such as obstructive (FEV1/FVC ≤ 30%), or restrictive (FVC \< 50% predicted) lung disease, neuromuscular disease, cancer, or renal failure
4. Unable to use PAP therapies due to physical issues (e.g. facial structural abnormalities) or cognitive issues (e.g. dementia)
5. Participants in whom positive airway pressure (PAP) therapy is medically contraindicated.
6. Uncontrolled hypertension (systolic ≥200 mm Hg/diastolic ≥120 mm Hg)
7. Pregnancy
8. Lactation
9. Implanted pacemaker / Cardiac Resynchronization Therapy (CRT) / implantable cardioverter-defibrillator (ICD) except for Medtronic devices with Opti Vol Algorithm
10. Incompetent patients or patients who, in the judgment of the investigator, are too unstable or are otherwise not capable of performing study procedures
11. Post-partum cardiomyopathy
12. Hypertrophic
13. Primary mitral valve stenosis
14. Patients requiring more than 50% supplemental oxygen or patients requiring more than 4 lpm oxygen
15. Patients with persistent ventricular arrhythmias (Premature ventricular coupling, periods of ventricular tachycardia)
16. Patients chronically classified (prior to admission) as New York Heart Association (NYHA) Class IV or American Heart Association Class D heart failure
17. Patients with glomerular filtration rate (GFR) \<30 or obligatory dialysis
18. Resting respiratory rate \>30 breaths per minute
19. Patients requiring mechanical ventilation or patients with an artificial airway (endotracheal or tracheostomy tube)
20. Patients with carbon monoxide toxicity
21. Patients with severe sepsis (defined as also an organ dysfunction due to an infection according to the Guidelines of the German Association of Sepsis, February 2010)
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Philips Technology Aachen Germany
UNKNOWN
RWTH Aachen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jörg Schröder, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Cardiology, Pneumology, Angiology and Intensive Care, Internal Medicine I (MK I), University Hospital Aachen (UKA)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of Aachen, Department of Cardiology
Aachen, Northrhine-Westfalia, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTC-A 12-117
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.